Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.

Trudel D, Labbé DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, Plante M, Grégoire J, Renaud MC, Bachvarov D, Têtu B, Bairati I.

Gynecol Oncol. 2013 Nov;131(2):357-61. doi: 10.1016/j.ygyno.2013.08.019. Epub 2013 Aug 27.

PMID:
23988418
2.

[Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].

Tu H, Huang H, Huang QD, Li Z, Feng YL, Liu JH.

Zhonghua Fu Chan Ke Za Zhi. 2012 Dec;47(12):928-33. Chinese.

PMID:
23324194
3.

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I.

Neoplasma. 2009;56(4):291-7.

PMID:
19473054
4.

First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.

Zylberberg B, Dormont D, Madelenat P, Daraï E.

Eur J Gynaecol Oncol. 2004;25(3):327-32.

PMID:
15171311
5.

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H.

Cancer. 2008 May 15;112(10):2211-20. doi: 10.1002/cncr.23438.

6.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

PMID:
16516283
7.

Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.

Yamamoto K, Oogi S, Inoue H, Kudoh K, Kita T, Kikuchi Y.

Curr Med Chem. 2004 Feb;11(4):425-8.

PMID:
14965223
8.

For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?

Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.

Am J Clin Oncol. 2008 Feb;31(1):39-42. doi: 10.1097/COC.0b013e318134ee6f.

PMID:
18376226
9.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
10.
11.

Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.

Fotiou S, Aliki T, Petros Z, Ioanna S, Konstantinos V, Vasiliki M, George C.

Gynecol Oncol. 2009 Aug;114(2):178-82. doi: 10.1016/j.ygyno.2009.04.025. Epub 2009 May 17.

PMID:
19450872
12.

A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.

Benedetti Panici P, Greggi S, Amoroso M, Scambia G, Battaglia FA, Gebbia V, Salerno G, Paratore MP, Mancuso S.

Int J Gynecol Cancer. 2001 Nov-Dec;11(6):438-44.

PMID:
11906546
13.

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Morrison J, Swanton A, Collins S, Kehoe S.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005343. Review. Update in: Cochrane Database Syst Rev. 2012;8:CD005343.

PMID:
17943850
14.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

PMID:
18025437
15.

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.

Tanner EJ, Black DR, Zivanovic O, Kehoe SM, Dao F, Konner JA, Barakat RR, Lichtman SM, Levine DA.

Gynecol Oncol. 2012 Jan;124(1):59-62. doi: 10.1016/j.ygyno.2011.09.011. Epub 2011 Oct 7.

PMID:
21982046
16.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

17.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
18.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
19.

Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy.

Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, Thoury A, Lhommé C, Duvillard P, Castaigne D.

Eur J Gynaecol Oncol. 2004;25(2):169-74.

PMID:
15032274
20.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

Supplemental Content

Support Center